The Health Technology Assessment (HTA) Policy and Methods Review (the HTA Review) was a key commitment under the 2022-27 Strategic Agreement between the Commonwealth and Medicines Australia, and aimed to evaluate Australia’s current HTA processes, funding and approval pathways to develop a set of recommendations to the Australian Government to address challenges identified. Consultation 1 focused on collating evidence and examples related to the HTA Review objectives and enabling early stakeholder input for the HTA Review. Australian Genomics’ submission highlighted the need for a unified HTA framework in Australia, and the need for alignment with recommendations of the New Frontier report, amongst other issues.
